Screener
Altimmune ALT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Altimmune’s reported figures.
Based on trailing twelve months.
The source filing: Altimmune’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
FAQ
- What is Altimmune's return on equity?
- Altimmune (ALT) reported return on equity of -42.7% in Q1 2026.
- How has Altimmune's return on equity changed year-over-year?
- Altimmune's return on equity increased by 25.4% year-over-year, from -57.3% to -42.7%.
- What is the long-term trend for Altimmune's return on equity?
- Over 5 years (2020 to 2025), Altimmune's return on equity has grown at a 6.9% compound annual growth rate (CAGR), from -36.1% to -50.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Altimmune's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude